by Jason Heaviland | Jun 12, 2026
ChatGJP: Discovery vs Targeted Exposomics Explained Should you use discovery exposomics or targeted exposomics? In this episode of ChatGJP, Panome Bio CEO Ed Weinstein explains the strengths of each approach and how they work together to provide a comprehensive...
by Jason Heaviland | Jun 2, 2026
ChatGJP: Exposomics, PFAS, and Clinical Trial Implications In this episode of ChatGJP, Panome Bio President and Co-Founder Tom Cohen explores the growing field of exposomics and its role in understanding how environmental exposures influence human health and disease....
by Jason Heaviland | Apr 14, 2026 | Uncategorized
In exposomics, there are two fundamentally different ways to explore the chemical world influencing human health and choosing the right one can make or break your study. Think of it like this: Are you searching for something specific or are you trying to discover what...
by Jason Heaviland | Mar 2, 2026
Chemical Exposure Profiling of Alzheimer’s Patients This webinar presents a comprehensive overview of chemical exposure profiling in Alzheimer’s patients using Panome Bio’s Targeted Exposomics™ and Discovery Exposomics™ platforms. Learn how quantitative exposure...
by Jason Heaviland | Feb 27, 2026 | Uncategorized
For 20 years, genomics has promised precision medicine. And it delivered. For rare diseases and select cancers. But for most chronic conditions?
Genetics explains only a fraction of risk. Type 2 diabetes. Alzheimer’s disease. Autoimmune disorders. Metabolic syndrome....
